MoonLake Immunotherapeutics (MLTX) is in Healthcare, Biotechnology, based in Switzerland, listed on NasdaqCM. Market cap 900.43M USD. 52-week range 8.80 to 23.29 USD. Data as of 2026-10-09.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, ...